本研究旨在评估尼群地平缓释片与沙库比替尼缬沙坦联合应用对合并高血压的糖尿病肾病（DN）患者的疗效。共纳入112例合并高血压的DN患者，随机分为对照组（应用尼群地平缓释片联合缬沙坦）和观察组（应用尼群地平缓释片联合沙库比替尼缬沙坦）。检测了肾功能、内皮功能和炎症反应。经过三个月的治疗，观察组的临床指标水平（糖化血红蛋白、空腹血糖、收缩压和舒张压）、肾功能指标（尿白蛋白排泄率、血尿素氮、血清肌酐和胱抑素C）、内皮功能指标（微量白蛋白、血管紧张素II、血栓调节蛋白和软骨寡聚糖基质蛋白）以及炎症反应因子（白细胞介素-6和肿瘤坏死因子-α）显著低于对照组。尼群地平缓释片联合沙库比替尼缬沙坦能有效缓解合并高血压的DN进展。版权所有©2023 Elsevier B.V. 保留所有权利。

This study aimed to evaluate the efficacy of nifedipine controlled-release tablets combined with sacubitril valsartan in diabetic nephropathy (DN) patients with hypertension. One hundred and twelve DN patients with hypertension were enrolled. They were randomly divided into the control group (treated with nifedipine controlled-release tablets combined with valsartan) and the observation group (treated with nifedipine controlled-release tablets combined with sacubitril valsartan). Renal function, endothelial function and inflammatory response were examined. After three-months treatment, the levels of clinical indexes (glycosylated hemoglobin, fasting blood glucose, systolic and diastolic blood pressure), renal function indicators (urinary albumin excretion rate, blood urea nitrogen, serum creatinine and cystatin C), endothelial function indicators (microalbumin, angiotensin II, thrombomodulin and cartilage oligomeric matrix protein) and inflammatory response factors (interleukin-6 and tumor necrosis factor-α) in the observation group were significantly lower than those in the control group. Nifedipine controlled-release tablets combined with sacubitril valsartan could effectively alleviate the progression of DN combined with hypertension.Copyright © 2023 Elsevier B.V. All rights reserved.